Nikolaos Papanas

Prof. Dr. Nikolaos Papanas

Department of Internal Medicine, Democritus University of Thrace, Komotini, Greece
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2004 in Platelets
Verified
Journal Article
Closed access
Nikolaos PapanasNikolaos Papanas
Nikolaos Papanas
GSG. Symeonidis
G. Symeonidis
EME. Maltezos
E. Maltezos
GMG. Mavridis
G. Mavridis
EKE. Karavageli
E. Karavageli
GLG. Lakasas
G. Lakasas
Aim of the study: To evaluate mean platelet volume (MPV) in type 2 diabetic versus non-diabetic patients, as well as to investigate the associations between MPV and diabetic complications. Materials and methods: This study included 416 patients divided into two groups. Group A comprised 265 type 2 diabetic patients (131 men) with a mean age of 67.4 ± 9.5 years and a mean diabetes duration of 14.5 ± 5.7 years. Group B comprised 151 non-diabetic patients (74 men) with a mean age of 68.6 ± 9.1 years. MPV (blood samples anticoagulated with sodium citrate) was measured in two blood cell counters (Sysmex SF 3000 and Cell-Dyn 3700). Results: MPV was significantly higher (P = 0.01) in group A (14.2 ± 2.2 fl) than in group B (7.1 ± 1.2 fl). In group A MPV was significantly higher (P = 0.043) in patients with retinopathy (15.8 ± 1.3 fl) than in patients without retinopathy (10.9 ± 1.1 fl) and also significantly higher (P = 0.044) in patients with microalbuminuria (15.6 ± 1.2 fl) than in patients without microalbuminuria (10.1 ± 1.2 fl). No association, however, was found in group A between MPV and age, gender, duration of diabetes, insulin dependency, BMI, HbA1c, coronary artery disease or dyslipidaemia. Conclusions: MPV is higher in type 2 diabetic patients than in non-diabetic patients. Among type 2 diabetic patients MPV is higher in those who have microvascular complications (retinopathy or microalbuminuria).

25 September 2018 in Endocrine Reviews
Verified
Journal Article
Closed access
PDF file
GBGidon J Bönhof
Gidon J Bönhof
CHChristian Herder
Christian Herder
ASAlexander Strom
Alexander Strom
Nikolaos PapanasNikolaos Papanas
Nikolaos Papanas
MRMichael Roden
Michael Roden
DZDan Ziegler
Dan Ziegler
Diabetic neuropathy, with its major clinical sequels notably neuropathic pain, foot ulcers, and autonomic dysfunction, is associated with substantial morbidity, increased risk of mortality, and reduced quality of life. Despite its major clinical impact, diabetic neuropathy remains underdiagnosed and undertreated. Moreover, the evidence supporting a benefit for causal treatment is weak at least in patients with type 2 diabetes, and current pharmacotherapy is largely limited to symptomatic treatment options. Thus, a better understanding of the underlying pathophysiology is mandatory for translation into new diagnostic and treatment approaches. Improved knowledge about pathogenic pathways implicated in the development of diabetic neuropathy could lead to novel diagnostic techniques that have the potential of improving the early detection of neuropathy in diabetes and prediabetes to eventually embark on new treatment strategies. Here we first provide an overview on the current clinical aspects and illustrate the pathogenetic concepts of (pre)diabetic neuropathy. We then describe the biomarkers emerging from these concepts and novel diagnostic tools and appraise their utility in the early detection and prediction of predominantly distal sensorimotor polyneuropathy (DSPN). Finally, we discuss the evidence for and limitations of the current and novel therapy options with particular emphasis on lifestyle modification and pathogenesis-derived treatment approaches. Altogether, recent years have brought forth a multitude of emerging biomarkers reflecting different pathogenic pathways such as oxidative stress and inflammation and diagnostic tools for an early detection and prediction of (pre)diabetic neuropathy. Ultimately, these insights should culminate in improving our therapeutic armamentarium against this common and debilitating or even life-threatening condition.

16 October 2016 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
KPKonstantinos Papatheodorou
Konstantinos Papatheodorou
Nikolaos PapanasNikolaos Papanas
Nikolaos Papanas
Maciej BanachMaciej Banach
Maciej Banach
ΔΠΔΗΜΗΤΡΙΟΣ ΠΑΠΑΖΟΓΛΟΥ
ΔΗΜΗΤΡΙΟΣ ΠΑΠΑΖΟΓΛΟΥ
MEMichael Edmonds
Michael Edmonds

29 January 2023 in The International Journal of Lower Extremity Wounds
Verified
Journal Article
Closed access
MLMiltos K. Lazarides
Miltos K. Lazarides
ILIrene Zacharo Lazaridou
Irene Zacharo Lazaridou
Nikolaos PapanasNikolaos Papanas
Nikolaos Papanas
Bibliometric analysis represents a new tool for classifying and quantitatively assessing bibliographic material (publications, citations, authors, institutions, etc) of a scientific discipline. Is a computer-assisted review and, therefore, it should follow the methodology of a systematic review. These analyses download bibliographic data from electronic databases analyzing them and extracting several indicators (such as the h-index). Analysis can be enhanced by adding scientific maps using specific software. These analyses are increasingly accepted in the medical literature to identify the most influential papers/authors/institutions on a given topic. During the last decade, there is a remarkable increase in the number of published bibliometric analysis articles.

1 June 2010 in Drug Safety
Verified
Journal Article
Closed access
PDF file
Nikolaos PapanasNikolaos Papanas
Nikolaos Papanas
EMEfstratios Maltezos
Efstratios Maltezos
DPDrNikolaos Papanas
DrNikolaos Papanas

1 May 2010 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
Nikolaos PapanasNikolaos Papanas
Nikolaos Papanas
EMEfstratios Maltezos
Efstratios Maltezos